Clinical Trials
8
Active:0
Completed:4
Trial Phases
4 Phases
Phase 1:1
Phase 2:1
Phase 3:5
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 3
5 (62.5%)Phase 1
1 (12.5%)Phase 2
1 (12.5%)Phase 4
1 (12.5%)A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants
Phase 3
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: sIPV+bOPVBiological: wIPV+bOPV
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Beijing Minhai Biotechnology Co., Ltd
- Target Recruit Count
- 300
- Registration Number
- NCT06752174
- Locations
- 🇨🇳
Shandong Provincial Center for Diseases Control and Prevention, Jinan, Shandong, China
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine
Phase 3
Recruiting
- Conditions
- Pneumococcal VaccinesPneumococcal Infections
- Interventions
- Biological: pneumococcal disease prevention
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Beijing Minhai Biotechnology Co., Ltd
- Target Recruit Count
- 500
- Registration Number
- NCT06608199
- Locations
- 🇮🇩
Faculty of Medicine, padjadjaran University, Bandung, Indonesia
🇮🇩Universitas Padjadjaran Bandung, Bandung, Indonesia
🇮🇩Faculty of Medicine Udayana University, Denpasar, Indonesia
A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months，7 Months-5 Years
Phase 4
Completed
- Conditions
- Pneumonia
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Beijing Minhai Biotechnology Co., Ltd
- Target Recruit Count
- 621
- Registration Number
- NCT06210737
- Locations
- 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China
A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
Phase 1
- Conditions
- COVID-19
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Beijing Minhai Biotechnology Co., Ltd
- Target Recruit Count
- 180
- Registration Number
- NCT04758273
- Locations
- 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China
A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
Phase 2
- Conditions
- COVID-19
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Beijing Minhai Biotechnology Co., Ltd
- Target Recruit Count
- 1000
- Registration Number
- NCT04756323
- Locations
- 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China
- Prev
- 1
- 2
- Next
News
No news found